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INTRODUCTION
Hydroxychloroquine (HCQ) is a disease-modifying anti-
rheumatic drug that is used commonly as an immunomodulato-
ry agent in the treatment of rheumatic diseases. It is considered 
a relatively safe drug. It is a pregnancy class C drug; however, 
years of retrospective and prospective clinical experience has 
shown that its administration does not lead to fetal teratogenic-
ity.1-5 Rarely, it can lead to retinal toxicity that can be prevented 
and detected by periodic ophthalmologic examinations.3 The 
most common cutaneous adverse reaction of HCQ is skin hy-
perpigmentation or a typical cutaneous drug eruption. Howev-
er, it also can cause rare and more significant dermatoses, such 
as erythema multiforme (EM) or erythema annulare centrifu-
gum.4 Erythema multiforme is an acute, self-limiting muco-
cutaneous hypersensitivity syndrome. Approximately 66% of 
patients who develop EM possess the HLA-DQB1*0301 26 al-
lele, which is present in only 31% of healthy subjects.6 We pres-
ent a severe case of EM induced by HCQ in a pregnant patient.
CASE REPORT
A 20-year-old pregnant African-American female presented 
to the rheumatology clinic at 16 weeks of gestation for the evalu-
ation of an elevated antinuclear antibody level, a malar rash, and 
concern for undiagnosed systemic lupus erythematosus (SLE). 
The patient met the American College of Rheumatology (ACR) 
classification criteria for SLE based on malar rash, painless oral 
ulcers, alopecia, strongly positive ANA of titer > 1280 speck-
led pattern, photosensitivity and arthritis which confirmed the 
diagnosis of SLE.7 The patient also had positive SSA and SSB 
(anti-Ro and anti-La) antibodies. Hence, HCQ therapy was ini-
tiated as an immunomodulatory agent to manage the SLE and 
prevent its potential complications for the patient and the fetus. 
A few days later, the patient presented to the emergency de-
partment with a painful, erythematous macular exanthem pre-
dominantly over the anterior and posterior aspects of her torso 
and upper extremities. Additionally, she had tense and flaccid 
bullae bilaterally on her breasts and chest. The patient had no 
evidence of mucosal involvement, although she developed ves-
icles on her cutaneous lips, forehead, and cheeks. Subsequently, 
she was admitted for further evaluation and pain management, 
with rheumatology and dermatology inpatient consultations.
During her hospitalization, the patient developed target le-
sions on her palms and upper extremities consistent with EM 
(Figures 1 and 2). The patient underwent a skin biopsy that 
confirmed the diagnosis (Figure 3). Infectious serologies and 
cultures, including those for herpes simplex virus (HSV) and 
Mycoplasma pneumoniae, were negative. She was not on any 
other medicine except HCQ. Due to the concern for potential 
toxic epidermal necrolysis in bullous lesions, the patient initial-
ly was started on intravenous immunoglobulin for four days. 
She was transitioned to oral prednisone, 40 mg daily, with a 
slow taper after skin biopsy confirmed diagnosis of EM. After 
initiation of prednisone therapy, her skin lesions improved 
with resolution of erythema and pain. She was discharged in 
stable condition on a steroid taper with resolving skin lesions.
Figure 1. Diffuse, scattered erythematous macules coalesced into 
patches with islands of sparing  on acral surface of left palm. 
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Figure 2. On day two, lesions began to form characteris-
tic “typical” targetoid lesions including two concentric 
rings surrounding a central area of bullae and/or necrosis. 
Figure 3. Skin biopsy demonstrated vacuolar interface lymphocyt-
ic dermatitis with ballooned and apoptic keratinocytes in the spi-
nous layer, melanoderma and a normal corneum. Viral inclusions, 
deep dermatitis, eosinophils, and neutrophils were absent. Direct 
immunofluorescence was non-reactive for IgG, IgA, IgM, and C3. 
DISCUSSION
Erythema multiforme, in its purest form, is an acute, self-lim-
ited but potentially recurrent skin disorder.8 It is observed pre-
dominantly in young adults, rarely in childhood, and has a slight 
male preponderance but no racial bias. Austrian dermatologist 
Ferdinand von Hebra first described this condition in 1860.9 The 
clinical hallmark of EM is the abrupt onset of typical target le-
sions forming within the first 24 hours. There may or may not be 
mucosal involvement. Clinically, the typical targets exhibit three 
distinct circles or “zones.” The innermost circle often initially is 
dusky and followed centripetally by two other concentric rings. 
The central circle subsequently may develop into a bulla and/
or crust later in the course of the disease. Additionally, atypi-
cal targets may be predominant, especially early in the course 
of the disease. Usually, there are only two different zones and 
there is generally a poorly defined border (< 3 cm in diameter).
Development of EM has been associated with herpes simplex 
virus (HSV) or Mycoplasma pneumoniae infections.10  Rarely (< 10% 
of cases), it is caused by drugs such as NSAIDS, sulfonamides, 
penicillin, antiepileptics, and antibiotics. According to the Med-
icines Control Agency, there have been four reports of EM since 
1964 related to hydroxychloroquine use.11 There is a single case 
report in the literature describing a case of erythema annulare 
centrifugum related to the use of hydroxychloroquine.12 In ad-
dition, there is a report of acute generalized exanthematous 
pustulosis.13 Furthermore, it is recognized that hydroxychloro-
quine can exacerbate psoriatic skin lesions,14 an effect thought to 
be related to inhibition of epidermal transglutaminase activity.15
Most importantly, EM is to be differentiated from acute dis-
seminated epidermal necrolysis, which includes Stevens–John-
son syndrome (SJS), toxic epidermal necrosis (TEN) and the 
SJS/TEN overlap.16 In our case, there was a definite predilec-
tion for atypical targets upon the patient’s presentation to the 
emergency room. The differential diagnosis was EM, SJS, and 
TEN. Our patient had no mucosal involvement, a variable that 
essentially is mandatory when diagnosing a patient with SJS 
or TEN. Also, the skin biopsy was consistent with EM, which 
ruled out the possibility of SJS, TEN, or bullous SLE. To the 
best of our knowledge, this is the first case of erythema mul-
tiforme due to hydroxychloroquine in a pregnant patient.
For clinicians, it can be a daunting task to make a clear and 
concise diagnosis when a patient presents with an abrupt on-
set of painful, blistering, and/or exfoliative skin lesions. First 
and foremost, a thorough history must be obtained. Medica-
tions and the duration or timing of exposure to medications 
are important when gathering the patient’s history. One also 
must conduct a comprehensive review of systems and tests 
to rule out potential infectious  etiologies that could cause an 
EM eruption, including but not limited to HSV or mycoplas-
ma  pneumoniae. Next, obtain a thorough physical examina-
tion of the patient’s skin, including the mucosal surfaces of 
the ocular, oropharyngeal and genital surfaces. Skin biopsy 
for both permanent and frozen sections may differentiate be-
tween SJS/TEN, EM, bullous LE, or a bullous drug eruption. 
Even then, the diagnosis often cannot be made on pathology 
alone, hence the importance of the role a detailed history and 
physical examination play in securing an accurate diagnosis.
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CONCLUSIONS
 Overall, hydroxychloroquine has a minimal and accept-
able side effect profile. It can be used in pregnancy, but its 
potential serious cutaneous side effects including SJS, TEN 
and EM should be considered prior to initiation. This extraor-
dinary case highlights promising new medical management 
of medication-induced erythema multiforme with intrave-
nous immunoglobulin and underscores the value of prompt 
diagnosis and supportive care. Prognosis reportedly is better 
for patients transferred promptly to a burn unit or intensive 
care unit.17 For unknown reasons, our patient was treated in 
the general medicine unit. In an age of increasing patient po-
ly-pharmacy, it is of paramount importance to consider all 
medication-induced side effects, both common and severe.
REFERENCES
1 Parke AL, Rothfield NF. Antimalarial drugs in pregnancy: The North 
American experience. Lupus 1996; 5(Suppl 1):S67-69. PMID: 8803915.
2 Khamashta MA, Buchanan NM, Hughes GR. The use of 
hydroxychloroquine in lupus pregnancy: The British ex-
perience. Lupus 1996; 5(Suppl 1):S65-66. PMID: 8803914.
3 Wolfe MS, Cordero JF. Safety of chloroquine in che-
mo suppression of malaria during pregnancy. Br Med J 
(Clin Res Ed) 1985; 290(6480):1466-1467. PMID: 3922534.
4 Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hy-
droxychloroquine in pregnant patients with connective tissue diseas-
es: A study of one hundred thirty-three cases compared with a con-
trol group. Arthritis Rheum 2003; 48(11):3207-3211. PMID: 14613284.
5 Centers for Disease Control and Prevention. CDC health information for 
international travel 2012. New York, NY: Oxford University Press, 2012. 
6 Khalil I, Lepage V, Douay C, et al. HLA DQB1*0301 al-
lele is involved in the susceptibility to erythema multi-
forme. J Invest Dermatol 1991; 97(4):697–700. PMID: 1940441.
7 Petri M, Orbai A, Alarcon G, et al. Derivation and vali-
dation of systemic lupus international collaborating clin-
ics classification criteria for systemic lupus erythemato-
sus. Arthritis Rheum 2012; 64(8): 2677-2686. PMID: 22553077.
8 Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. 2nd Edition. 
Rio de Janeiro: Elsevier Mosby, 2008. ISBN: 978-1-4160-2999-1.
9 Hebra F, Kaposi M. On Diseases of the Skin, Including the 
Exanthemata. London: The New Sydenham Society, 1866. 
10xSchalock PC, Brennick JB, Dinulos JG. Mycoplasma pneu-
moniae infection associated with bullous erythema multi-
forme. J Am Acad Dermatol 2005; 52(4):705-706. PMID: 15793531.
11xMedicines Control Agency, personal communication, 2001.
12xHudson LD. Erythema annulare centrifugum: An unusual case due to 
hydroxychloroquine sulfate. Cutis 1985; 36(2):129-130. PMID: 3161705.
13xAssier-Bonnet H, Saada V, Bernier M, Clerici T, Saiag P. Acute 
generalized exanthematous pustulosis induced by hydroxy-
chloroquine. Dermatology 1996; 193(1):70-71. PMID: 8864630.
14xSlagel GA, James WD. Plaquenil-induced erythroder-
ma. J Am Acad Dermatol 1985; 12(5):857-862. PMID: 3159760.
15xWolf R, Lo Schiavo A, Lombardi ML, Esposito C, Ruocco V. The 
in vitro effect of hydroxychloroquine on skin morphology and trans-
glutaminase. Int J Dermatol 1997; 36(9):704-707. PMID: 9352417.
16xAuquier-Dunant A, Mockenhaupt M, Naldi L, et al. Corre-
lations between clinical patterns and causes of erythema mul-
tiforme major, Stevens–Johnson syndrome, and toxic epider-
mal necrolysis: Results of an international prospective study. 
Arch  Dermatol 2002; 138(8):1019–1024. PMID: 12164739.
Keywords: erythema multiforme, hydroxychloroquine, pregnancy, systemic 
lupus erythematous
